iRegene Therapeutics raises US$28.9M Series C1 for AI-driven cell therapy platform

What's the deal? Chinese biotech startup iRegene Therapeutics has closed a US$28.9M Series C1 round to scale its AI-driven chemical induction platform. The company develops universal cell therapies targeting age-related diseases.

Why now? The convergence of AI and cell therapy is accelerating drug discovery timelines and lowering development costs. iRegene's platform uses artificial intelligence to guide chemical reprogramming of cells — an approach that could bypass some of the complexity and expense of traditional gene-editing methods.

The signal: The round reflects growing investor appetite for AI-bio crossover plays, particularly in China's biotech sector. As populations age globally, startups that can combine computational tools with regenerative medicine are drawing serious capital — even in a cautious funding environment.

Read more: pandaily.com